Scheduled maintenance until 6:00 AM EST.
Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumulation in Tauopathies (R01 Clinical Trial Not Allowed)
ID: 352941Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Mar 13, 2024 12:00 AM
  4. 4
    Due Jun 10, 2024 12:00 AM
Description

The National Institutes of Health (NIH) has posted a grant opportunity titled "Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumulation in Tauopathies (R01 Clinical Trial Not Allowed)". This grant aims to fund innovative research proposals that investigate the accumulation of misprocessed proteins in Tauopathies within specific brain regions and cell types. The goal is to shed light on dynamic changes in protein-misfolding responses in neuronal proteomes and their potential biological consequences during aging and the development of Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). The grant encourages collaborative efforts to create advanced single-cell or single-cell type proteogenomic platforms. The funding instrument for this opportunity is a grant, and there is no cost sharing or matching requirement. The grant has a maximum award ceiling of $500,000. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), non-domestic (non-U.S.) entities (Foreign Organizations), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. The closing date for this grant opportunity is June 10, 2024. For more information and to apply, visit the following link: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-017.html. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
Files
Title
Posted
Similar Opportunities
Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)". This grant is in the category of Health and falls under the funding instrument type of Grant. The grant does not require cost sharing or matching. The opportunity is discretionary and falls under CFDA number 93.866. The purpose of this grant is to support investigations into the cellular and molecular mechanisms of how and why multi-proteinopathy interactions drive worsening neurodegenerative processes and phenotypic outcomes in dementias with multiple etiologies. The grant aims to identify the mechanisms of co-pathology cellular and molecular interactions across brain regions and time, as well as determine the events that lead to worse phenotypic outcomes. The investigations should focus on a minimum of two relevant co-pathologies, such as tau, alpha-synuclein, TDP-43, TMEM106B, and vascular, with optional risk factors and co-morbidities. The grant is open to eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. Non-domestic (non-U.S.) Entities (Foreign Organizations) and non-U.S. components of U.S. Organizations are not eligible to apply. The grant has an award ceiling of $500,000. The closing date for applications is October 4, 2024, and the archive date is November 9, 2024. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html](http://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD and other ADRDs (R01 - Clinical Trial Not Allowed)". This grant aims to support research that delves deeper into the understanding of TDP-43 pathology and its causal relationships with phenotypic outcomes. It also seeks to explore the mechanistic interactions between TDP-43 and other co-pathologies, such as TMEM106B. The grant encourages comparisons between TDP-43 proteinopathies, including LATE, with or without AD-NC, and FTD and/or ALS, encompassing various aspects such as molecular, structural, cellular, genetic, -omic, anatomical, and neuropathological. The grant has a funding ceiling of $500,000 and does not require cost sharing or matching. The opportunity falls under the category of Health and is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, and Faith-based or Community-based Organizations, among others. The deadline for application submission is October 4, 2024. For more information and to apply, visit the following link: [Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-24-148.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Functional Target Validation for Alzheimer's Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed)". This grant aims to support the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer's Disease-Related Dementias (ADRDs). The goal is to de-risk subsequent translational research and accelerate the development of novel therapies for ADRD. The grant will provide support for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidates in cells or tissues and monitor their functional biological consequences in in vitro or in vivo disease models. The impact of the target modulation will be measured and cross-validated in different modalities across collaborating laboratories. The grant is open to eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments, Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. The deadline for applications is November 8, 2024. For more information, please visit the [grant opportunity website](http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-011.html).
Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed)". This grant aims to promote the discovery of cellular and molecular mechanisms that underlie brain blood vessels responses to passive anti-beta-amyloid immunotherapy, specifically focusing on amyloid-related imaging abnormalities (ARIA). The goal is to establish an understanding of molecular mechanisms that can be targeted to protect the blood brain barrier (BBB) and the brain blood vessels during therapeutic interventions that target beta-amyloid. The grant has a funding ceiling of $500,000 and does not require cost sharing or matching. The opportunity falls under the category of Health and is open to eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. Non-domestic (non-U.S.) Entities (Foreign Organizations) and non-domestic components of U.S. Organizations are not eligible to apply. The closing date for applications is November 5, 2024. For more information and to apply, visit the following link: [Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Amyloid Beta Immunotherapy (R01 - Clinical Trial Not Allowed)](http://grants.nih.gov/grants/guide/pa-files/PAR-24-198.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.